Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > Arrowhead to Present at Upcoming Scientific Conferences

Abstract:
Arrowhead Research Corporation (NASDAQ: ARWR), a targeted therapeutics company, today announced that academic collaborators and scientists from the company will present data on the Dynamic PolyConjugate™ (DPC) siRNA delivery system, the ARC-520 hepatitis B drug candidate, and the Homing Peptide™ platform at upcoming scientific conferences.

Arrowhead to Present at Upcoming Scientific Conferences

Pasadena, CA | Posted on February 2nd, 2013

"The pace of innovation by our scientists in Madison over the last year has been impressive," said Dr. Christopher Anzalone, President and Chief Executive Officer. "We have made important progress, particularly with new subcutaneous and tumor-targeted DPCs and our ARC-520 HBV clinical program, which we are eager to discuss at conferences and through peer-reviewed publications."

Scheduled conference presentations in February are as follows:

The Sixteenth International Symposium on Recent Advances in Drug Delivery Systems - Salt Lake City, Utah, February 3-6, 2013

A poster titled, "Hepatocyte-Targeted Melittin-Like Peptide (MLP) as A New Endosomolytic Excipient for Liver Delivery of Therapeutic siRNAs: Biodistribution and Elimination," will be presented by Vladimir S. Trubetskoy, PhD, Senior Scientist;

A poster titled, "Novel Maleic Anhydride Based Polymer Masking Reagents for Targeted siRNA Delivery with Dynamic Polyconjugates," will be presented by Andrei Blohkin, PhD, Senior Scientist;

An oral presentation titled, "Ligand-directed Therapy and Molecular Imaging Based on in vivo Phage Display Technology," will be presented by Renata Pasqualini, PhD, Helen Buchanan & Stanley Seeger Professor of Medicine and Experimental Diagnostic Imaging, Department of Genitourinary Medical Oncology - Research, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX;

An oral presentation titled, "Ligand-directed Targeting and Imaging in Translational Medicine," will be presented by Wadih Arap, MD, PhD, Stringer Professor of Medicine and Experimental Diagnostic Imaging, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX;

AsiaTIDES: Oligonucleotide and Peptide Research, Technology and Product Development - Tokyo, Japan, February 26-28, 2013

An oral presentation titled, "Dynamic Polyconjugate (DPC) Technology for Targeted siRNA Delivery," will be presented by David Lewis, PhD, Vice President, Biology and Madison Site Head.

####

About Arrowhead Research Corporation
Arrowhead Research Corporation is a clinical stage targeted therapeutics company with development programs in oncology, obesity, and chronic hepatitis B virus infection. The company is leveraging its platform technologies to design and develop peptide-drug conjugates (PDCs) that specifically home to cell types of interest while sparing off-target tissues, create targeted drugs based on the gene silencing RNA interference (RNAi) mechanism, and work with partners to create improved versions of traditional small molecule drugs.

For more information please visit www.arrowheadresearch.com, or follow us on Twitter @ArrowRes. To be added to the Company's email list to receive news directly, please send an email to

Safe Harbor Statement under the Private Securities Litigation Reform Act:

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including our ability to finance our operations, the future success of our scientific studies, our ability to successfully develop drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, and the enforcement of our intellectual property rights. Arrowhead Research Corporation's most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q discuss some of the important risk factors that may affect our business, results of operations and financial condition. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.

For more information, please click here

Contacts:
Arrowhead Research
Vince Anzalone, CFA
626-304-3400

The Trout Group, LLC
Lauren Glaser
646-378-2972

Copyright © Arrowhead Research Corporation

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

ICN2 researchers compute unprecedented values for spin lifetime anisotropy in graphene November 17th, 2017

Math gets real in strong, lightweight structures: Rice University researchers use 3-D printers to turn century-old theory into complex schwarzites November 16th, 2017

The stacked color sensor: True colors meet minimization November 16th, 2017

Nanometrics to Participate in the 6th Annual NYC Investor Summit 2017 November 16th, 2017

Nanomedicine

Nanobiotix presented new clinical and pre-clinical data confirming NBTXR3’s significant potential role in Immuno-Oncology at SITC Annual Meeting November 14th, 2017

Arrowhead to Present at 29th Annual Piper Jaffray Healthcare Conference November 14th, 2017

A new way to mix oil and water: Condensation-based method developed at MIT could create stable nanoscale emulsions November 8th, 2017

Nanoshells could deliver more chemo with fewer side effects: In vitro study verifies method for remotely triggering release of cancer drugs November 8th, 2017

Announcements

ICN2 researchers compute unprecedented values for spin lifetime anisotropy in graphene November 17th, 2017

Math gets real in strong, lightweight structures: Rice University researchers use 3-D printers to turn century-old theory into complex schwarzites November 16th, 2017

The stacked color sensor: True colors meet minimization November 16th, 2017

Nanometrics to Participate in the 6th Annual NYC Investor Summit 2017 November 16th, 2017

Events/Classes

Nanometrics to Participate in the 6th Annual NYC Investor Summit 2017 November 16th, 2017

Arrowhead to Present at 29th Annual Piper Jaffray Healthcare Conference November 14th, 2017

Leti Will Present 11 Papers and Host More-than-Moore Technologies Workshop November 14th, 2017

TUBALL nanotube-based concentrates recognised as the most innovative raw material for composites by JEC Group November 7th, 2017

Research partnerships

EC Project Aims at Creating and Commercializing Cyber-Physical-System Solutions November 14th, 2017

Leti Joins DARPA-Funded Project to Develop Implantable Device for Restoring Vision November 9th, 2017

Nanoshells could deliver more chemo with fewer side effects: In vitro study verifies method for remotely triggering release of cancer drugs November 8th, 2017

Ames Laboratory, UConn discover superconductor with bounce October 25th, 2017

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project